Compounds for reversing drug resistance

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 5/04 (2006.01) A61K 38/04 (2006.01) C07K 7/06 (2006.01)

Patent

CA 2189978

The invention features novel peptide derivatives called Reversins, and provides for their use in a method of reducing the activity of the multi-drug transporter protein MDR1 in order to overcome multidrug resistance in a mammal. The peptide derivatives are of the formula (I) X1n-X2-X3(X4)n-X5, wherein n is 0 or 1, and each n is the same or different; X1 is BOC, BOC-Asu, Z-Asu, benzyloxycarbonyl, Glu(OBzl)-OBzl, Trp-OMe, Trp-Phe-OMe, Phe-Trp-OMe, Phe-Phe-OtBu, Trp-Trp-OtBu, indoloacetyl, benzoyl, an alkylamine of 1-4 carbons, dibenzylamide, tryptamide, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide or dicyclohexylamide; X2 is Glu(OBzl), Asp(OBzl), succinyl, O,O-dibenzoyltartaroyl, diphenoyl, muconyl, Thx, Cpa, Asu, Nal, Pen, Phg, Dbt, Lys(BOC), Lys(Z), Cys(Bzl), Thr(Bzl), Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Phe, Tyr(Bzl), or Ser(Bal); X3 is Asp, Asu, Lys, Glu, Trp, Thx, Cpa, Nal, Pen, Phg, Dbt, Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Tyr, Phe, or Tyr(Bzl); X4 is BOC-Glu(OBzl), Glu(OBzl), Asu, OBzl, Bzl, BOC, BOC-Lys(BOC), Z-Glu(OtBu), Asp(OBzl), Asp(OBz)-OBzl, benzyloxycarbonyl, O-(cyclo-hexyl), fluorenylmethyl ester, Glu(OtBu), Glu(OtBu)-OBzl, 1-amino-adamantine, aminomethylcyclohexane, indoline, phenylethylamide, or dicyclohexylamide; and X5 is OMe, OBzl, OtBu, Phe-OMe, -O- (cyclohexyl), Trp-OMe, (chlorophenyl)-isobutylamide, fluorenylmethyl ester, ONp, 1-aminoadamantane, aminomethylcyclohexane, indoline, phenylethylamide, or dicyclohexylamide.

L'invention concerne de nouveaux dérivés de peptides appelés réversines, ainsi qu'un procédé de mise en application desdits dérivés visant à limiter l'activité d'une protéine de transport d'agents thérapeutiques médicamenteux multiples (MDR1), afin d'annihiler, chez un mammifère, la résistance auxdits agents. Ces dérivés sont représentés par la formule (I): X?1¿¿n?-X?2¿-X?3¿(X?4¿)¿n?-X?5¿ dans laquelle n est 0 ou 1, et chaque n est semblable ou différent; X?1¿ représente BOC, BOC-Asu, Z-Asu, benzyloxycarbonyle, Glu(OBzl)-OBzl, Trp-OMe, Trp-Phe-OMe, Phe-Trp-OMe, Phe-Phe-OtBu, Trp-Trp-OtBu, indoloacétyle, benzoyle, une alkylamine de 1-4 carbones, dibenzylamide, tryptamide, 1-amino-adamantine, aminométhylcyclohexane, indoline, phényléthylamide ou dicyclohexylamide; X?2¿ représente Glu(OBzl), Asp(OBzl), succinyle, O,O-dibenzoyltartaroyle, diphénoyle, muconyle, Thx, Cpa, Asu, Nal, Pen, Phg, Dbt, Lys(BOC), Lys(Z), Cys(Bzl), Thr(Bzl), Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Phe, Tyr(Bzl), ou Ser(Bal); X?3¿ représente Asp, Asu, Lys, Glu, Trp, Thx, Cpa, Nal, Pen, Phg, Dbt, Glu(OtBu), tert.-Leu, Leu, Nle, Pro, Tyr, Phe, ou Tyr(Bzl); X?4¿ représente BOC-Glu(OBzl), Glu(OBzl), Asu, OBzl, Bzl, BOC, BOC-Lys(BOC), Z-Glu(OtBu), Asp(OBzl), Asp(OBz)-OBzl, benzyloxycarbonyle, O-(cyclo-hexyle), fluorenylméthyl ester, Glu(OtBu), Glu(OtBu)-OBzl, 1-amino-adamantine, aminométhylcyclohexane, indoline, phényléthylamide, ou dicyclohexylamide; et X?5¿ représente OMe, OBzl, OtBu, Phe-OMe, -O-(cyclohexyle), Trp-OMe, (chlorophényle)-isobutylamide, fluorénylméthyl ester, ONp, 1-aminoadamantane, aminométhylcyclohexane, indoline, phényléthylamide ou dicyclohexylamide.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Compounds for reversing drug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for reversing drug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for reversing drug resistance will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1954662

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.